- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05278988
A Study of Ultrashort PRS Regimen V in the Treatment of MDR-TB
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Shortening the course of treatment based on effective therapy can significantly improve patient compliance and reduce the public health burden.Research on optimal drug combination regimens to further shorten the duration and improve the efficacy of multidrug-resistant tuberculosis treatment is an important research direction.The PRS (parabolic response surface, FSC.II) system is an enhanced use of FSC to better identify and optimize optimal drug combinations.In preliminary studies, it was determined that PRS Regimens V (bedaquiline, delamanid, clofazimine, pyrazinamide)was superior to other regimens and would be a promising combination for XDR-TB because it does not contain fluoroquinolones or aminoglycosides. Preliminary trials have demonstrated that this regimen (PRS Regimens IV) can significantly reduce the duration of treatment required for MDR-TB and achieve a relapse-free cure.
Therefore, the investigators conducted an exploratory, prospective, randomized, positive-controlled, open, multicenter clinical study of this new regimen to observe the efficacy, safety, and recent relapse rate of the new regimen in the treatment of multidrug-resistant tuberculosis.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Shanghai Pulmonary Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Untreated newly diagnosed patients with rifampicin resistant (RR) or multidrug resistant (MDR)-TB.
- Newly treated patients: at least twice confirmed by molecular biology or phenotypic drug susceptibility test to have RR- or MDR-TB; Retreated patients: confirmed once by molecular biology or phenotypic drug susceptibility test to have RR- or MDR-TB.
- Age between 18 and 65.
- No abnormality on EKG.
- Able to understand and sign informed consent form.
Exclusion Criteria:
- Presence of extrapulmonary TB (including tuberculous pleurisy);
- History of allergic reaction to any of the drugs used in the study;
Presence of any of the following conditions that can lead to prolonged QT:
- During screening process, ECG shows QT or QTc interval ≥ 450 ms (permit one non-prescheduled retest within the screening period to re-evaluate the testees' qualification);
- Pathological Q waves (any Q wave duration of > 40 ms or depth > 0.4-0.5 mV);
- Evidence of ventricular pre-excitation (such as Wolff-Parkinson-White Syndrome);
- EKG shows evidence of complete or clinically significant incomplete left or right bundle branch block;
- Evidence of 2nd or 3rd degree heart block;
- Intraventricular conduction delay, QRS durations > 120 ms;
- Slow heart rate, defined as sinus heart rate < 50 bpm;
- Having personal or family history of long QT syndrome;
- Having heart disease, symptomatic or asymptomatic arrhythmia, excluding sinus arrhythmia;
- Fainting (i.e., cardiogenic fainting, not including vasovagal syncope or seizure)
- Having risk factors for Torsade de pointes ventricular tachycardia (e.g. heart failure, hypokalemia, hypomagnesemia)
- Pregnancy or liver, kidney, metabolic, autoimmunity, neurological, psychological or endocrine disease, blood system disease, malignant cancer, long-term users of immunosuppressant drugs.
- Alcoholism
- Any patients, based on the judgement of the study medical researchers who are not suitable to participate in the trial or unlikely to complete the trial.
- Participating in another clinical trial at the same time.
- History of non-compliance in other clinical trials.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Group A
Treatment according to WHO MDR-TB treatment guidelines (2019).
|
Treatment according to WHO MDR-TB treatment guidelines (2019)
Other Names:
|
EXPERIMENTAL: Group B(PRS Regimen V)
bedaquiline, delamanid, clofazimine, pyrazinamide
|
PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
patient cure rate
Time Frame: Through study completion, an average of 18 months
|
Assessment of cure rate :
|
Through study completion, an average of 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early bactericidal activity (EBA)
Time Frame: treatment initiation (Day 0; D0) and on Day 2 (D2), Day 7 (D7), and Day 14 (D14) after the start of treatment
|
Collect patient sputum between 16:00 to 8:00 the next morning before taking drugs prior to treatment initiation (Day 0; D0) and on Day 2 (D2), Day 7 (D7), and Day 14 (D14) after the start of treatment
|
treatment initiation (Day 0; D0) and on Day 2 (D2), Day 7 (D7), and Day 14 (D14) after the start of treatment
|
Time to culture positivity
Time Frame: Through study completion, an average of 18 months
|
culture using MGIT 960 and observe the time to detection of positive growth.
|
Through study completion, an average of 18 months
|
Sputum conversion rate
Time Frame: Through study completion, an average of 18 months
|
ompare patient sputum conversion rate between the two groups at one month and two months.
|
Through study completion, an average of 18 months
|
Radiology changes
Time Frame: Through study completion, an average of 18 months
|
"Significant absorption" is defined as lesion absorption ≥ ½. "Absorption" is defined as lesion absorption ≤ ½. "No change" if the original lesion has no clear change.
"Worsened" if the original lesion is enlarged or has spread.
"Closure" if the original cavity is enclosed or enclosed by blockage.
"Shrinkage" if diameter of the original cavity decreased by ≥1/2.
"No change" if diameter of the original cavity decreases by <1/2.
"Enlarged" if diameter of the original cavity increases by >1/2.
|
Through study completion, an average of 18 months
|
Relapse rate one and two years after treatment completion.
Time Frame: At 3, 6, 12, 18, and 24 months
|
follow up at 3, 6, 12, 18, and 24 months after treatment completion
|
At 3, 6, 12, 18, and 24 months
|
Time to Cure by Primary Endpoint criteria
Time Frame: 6-9 month
|
Time to Cure by Primary Endpoint criteria
|
6-9 month
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sha wei, Shanghai Pulmonary Hospital, Shanghai, China
Publications and helpful links
General Publications
- Silva A, Lee BY, Clemens DL, Kee T, Ding X, Ho CM, Horwitz MA. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model. Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):E2172-9. doi: 10.1073/pnas.1600812113. Epub 2016 Mar 28.
- Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7. doi: 10.5588/ijtld.14.0100.
- Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92. doi: 10.1164/rccm.201001-0077OC. Epub 2010 May 4.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- K21-024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MDR-TB
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Centre for the AIDS Programme of Research in South...Amsterdam Institute for Global Health and Development; Global Alliance for... and other collaboratorsRecruitingTuberculosis | Drug Resistant Tuberculosis | MDR-TB | XDR-TBNigeria, South Africa, Ethiopia
-
Shanghai Pulmonary Hospital, Shanghai, ChinaHuashan Hospital; Shanghai Public Health Clinical Center; No.85 Hospital, Changning...RecruitingImmunotherapy | MDR-TBChina
-
IUATLD, IncMedical Research Council; Institute of Tropical Medicine, Belgium; Liverpool... and other collaboratorsCompletedMDR-TBEthiopia, Georgia, India, Moldova, Republic of, Mongolia, South Africa, Uganda
-
Jan-Willem C AlffenaarUniversity of Virginia; Kibong'oto Infectious Diseases HospitalCompleted
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant | Extensively Drug-Resistant Tuberculosis | Tuberculosis, MDR | XDR-TB | Pre-XDR-TBSouth Africa, Russian Federation, Georgia, Moldova, Republic of
-
Ina-RespondNational Institute of Health Research and Development, Ministry of Health... and other collaboratorsCompletedLung Tuberculosis | MDR TBIndonesia
-
University of OxfordCompleted
-
University of OxfordCompleted
-
University of OxfordMedical Research CouncilCompleted
Clinical Trials on MDR-TB Treatment Regimen(WHO)
-
Medecins Sans Frontieres, NetherlandsImperial College London; Ministry of Health, Republic of UzbekistanUnknownMultidrug Resistant TuberculosisUzbekistan
-
Huashan HospitalNot yet recruitingMultidrug Resistant TuberculosisChina
-
National Institute of Allergy and Infectious Diseases...Otsuka Pharmaceutical Development & Commercialization, Inc.RecruitingHIV Infections | TuberculosisTanzania, India, South Africa, Botswana
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingTuberculosis | Rifampicin Resistant TuberculosisBrazil, India, South Africa, Tanzania, Thailand
-
Shanghai Pulmonary Hospital, Shanghai, ChinaHuashan Hospital; Shanghai Public Health Clinical Center; No.85 Hospital, Changning...RecruitingImmunotherapy | MDR-TBChina
-
Boston UniversityUniversity of Florida; WestatWithdrawnTuberculosis Multi Drug Resistant Active
-
Janssen Infectious Diseases BVBACompletedTuberculosisChina, Ukraine, Korea, Republic of, Peru, Estonia, Kenya, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey
-
ANRS, Emerging Infectious DiseasesEuropean and Developing Countries Clinical Trials Partnership (EDCTP); European...RecruitingTuberculosis | HIV-1-infection | Immuno-DeficiencyUganda, Cambodia, Cameroon, Guinea, Vietnam, Zambia
-
Janssen Infectious Diseases BVBACompletedTuberculosisSouth Africa, Peru, Latvia, Philippines, Russian Federation, Thailand, Brazil, India
-
Institute for Clinical Effectiveness and Health...University of WashingtonActive, not recruitingTuberculosis | Treatment AdherenceArgentina